(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Reports that Arcadia clinical study shows potential value of AZD1656 treatment for Covid-19 patients. The new data analysis comes from St George Street Capital Ltd, which runs the trial with Excalibur Medicines Ltd for the treatment, in which Cizzle holds a "significant" royalty-bearing economic interest. Read More
(Alliance News) - Cizzle Biotechnology Holdings PLC shares jumped on Monday after it announced that it acquired an additional 5% interest in the commercialisation of the Covid-19 treatment AZD 1656. Read More
